Deep knowledge on
small-molecule drugs and
the 90,000 global patents
covering them

Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: LYRICA

« Back to Dashboard
Lyrica is a drug marketed by Pf Prism Cv and is included in two NDAs. It is available from eight suppliers. There are three patents protecting this drug and two Paragraph IV challenges.

This drug has sixty-three patent family members in thirty countries.

The generic ingredient in LYRICA is pregabalin. There are twenty-eight drug master file entries for this compound. Eight suppliers are listed for this compound. There are nine tentative approvals for this compound. Additional details are available on the pregabalin profile page.

Summary for Tradename: LYRICA

Suppliers / Packagers: see list57
2013 Sales:$2,415,254,000

Clinical Trials for: LYRICA

Role of Pregabalin in Treatment of Post-Op Pain in Fracture Patients
Status: Completed Condition: Post-operative Pain

A Randomized Double-Blind Study Testing the Effects of Pregabalin on Diabetic Neuropathy
Status: Completed Condition: Diabetic Neuropathy

PharmacofMRI of Anxiolytic Medications (Pregabalin)
Status: Completed Condition: Anxiety Disorders

A Placebo-Controlled Trial of Pregabalin (Lyrica) for Irritable Bowel Syndrome
Status: Active, not recruiting Condition: Irritable Bowel Syndrome

Safety And Efficacy Of Lyrica (Regulatory Post Marketing Commitment Plan)
Status: Active, not recruiting Condition: Neuralgia

Safety And Efficacy In Long Term Use Of Lyrica (Regulatory Post Marketing Commitment Plan)
Status: Active, not recruiting Condition: Neuropathic Pain

Efficacy and Safety of KW21052 Compared to Lyrica in the Diabetic Patients With Neuropathic Pain
Status: Not yet recruiting Condition: Diabetic Neuropathy

Effect of Oral Pregabalin on Spinal Neurotransmitters in Patients Undergoing Knee Replacement
Status: Completed Condition: PAIN

The Effects of Pregabalin on Postoperative Pain After Cardiac Surgery
Status: Recruiting Condition: Postoperative Pain

A Study of Pregabalin (Lyrica) Augmentation in Serotonin Reuptake Inhibitor-Refractory Obsessive Compulsive Disorder
Status: Recruiting Condition: Obsessive-Compulsive Disorder

Courtesy of
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pf Prism Cv
SOLUTION;ORAL022488-001Jan 4, 2010RXYes6,001,876<disabled>Y <disabled>
Pf Prism Cv
SOLUTION;ORAL022488-001Jan 4, 2010RXYes<disabled><disabled>
Pf Prism Cv
CAPSULE;ORAL021446-006Dec 30, 2004RXNoRE41920<disabled> <disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: LYRICA

Drugname Dosage Strength RLD Submissiondate
pregabalinOral Solution20 mg/mLLyrica5/19/2010
pregabalinCapsules25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg and 300 mgLyrica12/30/2008

International Patent Family for Tradename: LYRICA

Country Document Number Publication Date
Japan3693258Sep 07, 2005
CroatiaP970387Oct 31, 1998
Czech Republic9402849Mar 15, 1995
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a trial or see the database preview and plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn